ReviewEuropean journal of medical research2025
Recent advances in biomarkers for detection and diagnosis of sepsis and organ dysfunction: a comprehensive review.
Review in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- The cellular response capacity (CRC) as a novel immunomonitoring approach in sepsis.Military Medical Research · 2026Article
- Artificial intelligence in biomarker discovery for diseases: diagnostic and therapeutic prospects.Signal transduction and targeted therapy · 2026Review
- Physiological Phenotypes in Comatose ICU Patients: A Retrospective Multidimensional Analysis.Diagnostics (Basel, Switzerland) · 2026Article
- Tenascin-C, presepsin (SCD14-ST), and neutrophil-to-lymphocyte ratio as complementary circulating biomarkers for sepsis-associated organ dysfunction and 28-day all-cause mortality: A biomarker-enriched prognostic model.Journal of medical biochemistry · 2026Article
- ASP-COMPLEX: redefining antimicrobial stewardship to improve outcomes in high-risk patients with severe infections.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Review
- Prognostic Value of 48-Hour Biomarker Reassessment Beyond Admission SOFA for 28-Day Mortality in Sepsis.Diagnostics (Basel, Switzerland) · 2026Article
- Diagnostic Performance and Prognostic Value of Serum Amyloid A in Patients with Bloodstream Infection.Diagnostics (Basel, Switzerland) · 2026Article
- Early ΔNLR Outperforms Baseline Inflammatory Markers in Predicting Short-Term Outcomes in Sepsis.Diagnostics (Basel, Switzerland) · 2026Article
- Predictive and Prognostic Biomarkers in Pediatric Intussusception-A Systematic Review.Journal of clinical medicine · 2026Review
- Development and validation of clinical phenotypes in sepsis-associated liver injury using multi-algorithm consensus classification: a retrospective cohort study.BMC infectious diseases · 2026Article
- CX3CR1-mediated immune networks in sepsis: implications for precision therapy.Cell death discovery · 2026Review
- Extracellular Vesicle-Derived MicroRNAs' Value in Diagnosing and Predicting Clinical Outcomes in Patients with COVID-19 and Bacterial Sepsis.International journal of molecular sciences · 2026Article
- Early enteral nutrition and dynamic metabolic-inflammatory trajectories in sepsis: a retrospective cohort study.Frontiers in medicine · 2026Article
- Dynamic prognostic prediction in sepsis using longitudinal blood gas trajectories: development and external validation.Frontiers in medicine · 2026Article
- Peripheral blood biomarkers in PD-1/PD-L1 immunotherapy: distinguishing predictive from prognostic biomarkers.Frontiers in immunology · 2026Review
- Quantification of the Actin-Binding Protein Flightless-I in Human Serum by Automated Western Blot System and Investigation of Its Diagnostic Potential in Sepsis.Biomedicines · 2025Article
- Circulatory biomarkers for microbial infections.Journal of circulating biomarkersArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis is life-threatening inflammatory disease, and its pathogenesis and prognostic factors remain unclear. In addition, the symptoms and signs of sepsis patients lack specificity, which makes the diagnosis, treatment and prognosis evaluation of sepsis extremely difficult. Recently, with the emergence and development of detection technologies, various sepsis-related biomarkers have emerged. Biomarkers could be considered as indicators of either infection or dysregulated host response or response to treatment and/or aid clinicians to prognosticate patient risk. Therefore, searching for reliable biomarkers and evaluating their role in sepsis is envisaged to aid clinical decision-making. This article reviews the advances in research on sepsis biomarkers and their application in the early prediction of organ dysfunction to improve our understanding of current sepsis biomarkers and provide a reference for the application of biomarkers in the clinical diagnosis, treatment, and prognosis of sepsis. Besides, we propose that the combining multiple biomarkers is expected to be a more accurate and comprehensive strategy to evaluate the condition and prognosis of sepsis patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.